NVO vs TMO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NVO presents a dichotomy between elite profitability and deteriorating growth. The Piotroski F-Score of 4/9 indicates stable but non-improving financial health, while the current price of $42.22 trades at a significant premium to both the Graham Number ($23.58) and Intrinsic Value ($25.27). Despite an exceptional ROE of 60.7% and strong margins, the company is facing negative YoY revenue (-7.6%) and earnings growth (-4.7%), resulting in a high PEG ratio of 4.53. The outlook is tempered by a bearish technical trend and liquidity concerns, though supported by a strong dividend profile and analyst 'Buy' ratings.
TMO exhibits exceptional operational health with a Piotroski F-Score of 8/9, indicating strong financial stability and efficiency. However, the stock is currently trading at a significant premium, with a current price of $513.98 far exceeding both the Graham Number ($237.97) and the growth-based Intrinsic Value ($371.44). While analyst sentiment remains strongly bullish with a target of $647.38, this is countered by bearish insider activity and a negative technical trend. The outlook is balanced between high-quality fundamentals and a stretched valuation.
Compare Another Pair
Related Comparisons
NVO vs TMO: Head-to-Head Comparison
This page compares Novo Nordisk A/S (NVO) and Thermo Fisher Scientific Inc. (TMO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.